A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

Under the agreement, Mankind Pharma will have the exclusive rights to register, import, market, sell, and distribute Sintilimab in India. Credit: Piotr Swat/Shutterstock. Mankind Pharma has entered ...

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

Hydrocodone IR is under clinical development by Elysium Therapeutics and currently in Phase I for Opium (Opioid) Addiction.

Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome.

CSTI-500 is under clinical development by ConSynance Therapeutics and currently in Phase I for Prader-Willi Syndrome (PWS).

Though still below boom levels seen a few years ago, 2024 compares favourably to 2023, and signs suggest that growth will continue into 2025.

COYA-301 is under clinical development by Coya Therapeutics and currently in Phase II for Alzheimer's Disease.

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...